Top Tweets for #AMLSM
Hear new findings from a Phase Ib/II trial investigating azacitidine, venetoclax, and ivosidenib in patients with IDH1-mutated acute myeloid #leukemia. 🚨
Watch our interview with @JenMarvinPeek of @UTMDAnderson:
🎥 https://t.co/TPTZquVUc2
#AMLsm #Leusm #TrialUpdate #CTSM #HemOnc #ASCO26
A revised prognostic model for patients with acute myeloid leukemia and first relapse [Jul 28, 2025]
@niek_maas et al. @BloodAdvances
https://t.co/XqXxfD9nj9 #AMLsm #leusm
![mtmdphd's tweet photo. A revised prognostic model for patients with acute myeloid leukemia and first relapse [Jul 28, 2025]
@niek_maas et al. @BloodAdvances
https://t.co/XqXxfD9nj9 #AMLsm #leusm https://t.co/by0sXgwsey](https://pbs.twimg.com/media/HPIL6THXQAAhO0c.jpg)
Check out the great summary @SoundCloud and our @TheIACH webinar on peri-transplant Rx of #MDSsm and #AMLsm Thanks for the opportunity! @BipinSavani @Mohty_EBMT Grateful for support for #INTERCEPT clinic @DrAdetolaKassim @DholariaMD @VUMCDiscoveries @VUMChealth @jordanberlin5
💡 𝘐𝘈𝘊𝘏 𝘞𝘦𝘣𝘪𝘯𝘢𝘳 𝘐𝘯𝘴𝘪𝘨𝘩𝘵𝘴: 𝘉𝘦𝘺𝘰𝘯𝘥 𝘵𝘩𝘦 𝘞𝘦𝘣𝘪𝘯𝘢𝘳
𝗣𝗿𝗲𝘃𝗲𝗻𝘁𝗶𝗻𝗴 𝗥𝗲𝗹𝗮𝗽𝘀𝗲 𝗔𝗳𝘁𝗲𝗿 𝗔𝗹𝗹𝗼𝗴𝗲𝗻𝗲𝗶𝗰 𝗧𝗿𝗮𝗻𝘀𝗽𝗹𝗮𝗻𝘁𝗮𝘁𝗶𝗼𝗻 𝗶𝗻 𝗛𝗶𝗴𝗵-𝗥𝗶𝘀𝗸 𝗠𝘆𝗲𝗹𝗼𝗶𝗱 𝗠𝗮𝗹𝗶𝗴𝗻𝗮𝗻𝗰𝗶𝗲𝘀: 𝗔𝗿𝗲 𝗪𝗲 𝗘𝗻𝘁𝗲𝗿𝗶𝗻𝗴 𝘁𝗵𝗲 𝗘𝗿𝗮 𝗼𝗳 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 𝗣𝗼𝘀𝘁-𝗧𝗿𝗮𝗻𝘀𝗽𝗹𝗮𝗻𝘁 𝗖𝗮𝗿𝗲?
🎙️𝘛𝘶𝘯𝘦 𝘪𝘯𝘵𝘰 𝘢 𝘯𝘦𝘸 𝘱𝘰𝘥𝘤𝘢𝘴𝘵:
https://t.co/W4syATxmg5
🧑💻𝘎𝘢𝘪𝘯 𝘬𝘦𝘺 𝘵𝘢𝘬𝘦𝘢𝘸𝘢𝘺𝘴 𝘧𝘳𝘰𝘮 𝘰𝘶𝘳 𝘐𝘈𝘊𝘏 𝘗𝘰𝘴𝘵 𝘊𝘰𝘯𝘨𝘳𝘦𝘴𝘴 𝘞𝘦𝘣𝘪𝘯𝘢𝘳:
𝗠𝗮𝗻𝗮𝗴𝗶𝗻𝗴 𝗵𝗶𝗴𝗵 𝗿𝗶𝘀𝗸 𝗺𝘆𝗲𝗹𝗼𝗶𝗱 𝗺𝗮𝗹𝗶𝗴𝗻𝗮𝗻𝗰𝗶𝗲𝘀 𝗮𝗳𝘁𝗲𝗿 𝗮𝗹𝗹𝗼-𝗛𝗖𝗧: 𝗩𝗮𝗻𝗱𝗲𝗿𝗯𝗶𝗹𝘁 𝗜𝗻𝘁𝗲𝗿𝗰𝗲𝗽𝘁 𝗖𝗹𝗶𝗻𝗶𝗰 𝗠𝗼𝗱𝗲𝗹
𝘞𝘢𝘵𝘤𝘩 𝘵𝘩𝘦 𝘸𝘦𝘣𝘪𝘯𝘢𝘳 𝘧𝘰𝘳 𝘍𝘙𝘌𝘌🔽
https://t.co/HJNkCEGU9x
@Mohty_EBMT @drsomedeb
New publication📝 Phase I KOMET-007 trial results, published in @BloodPortfolio, show ziftomenib + Ven + Aza achieved a 46% CRc rate at the recommended 600 mg ziftomenib dose, in adults with R/R NPM1-mutated AML.
Learn more about NPM1-mutated AML: https://t.co/ZWbQv2dPL4
#AMLsm #leusm #MedNews #MedEd
Please join as I discuss data on post-SCT outcomes and potential strategies to prevent relapses in higher-risk #MDSsm and #AMLsm in this upcoming webinar @TheIACH Will discuss our new clinic @VUMCDiscoveries INTERCEPT. Grateful for the opportunity! @BipinSavani @DrAdetolaKassim
Join us for the upcoming IACH Webinar:
𝗠𝗮𝗻𝗮𝗴𝗶𝗻𝗴 𝗵𝗶𝗴𝗵 𝗿𝗶𝘀𝗸 𝗺𝘆𝗲𝗹𝗼𝗶𝗱 𝗺𝗮𝗹𝗶𝗴𝗻𝗮𝗻𝗰𝗶𝗲𝘀 𝗮𝗳𝘁𝗲𝗿 𝗮𝗹𝗹𝗼-𝗛𝗖𝗧: 𝗩𝗮𝗻𝗱𝗲𝗿𝗯𝗶𝗹𝘁 𝗜𝗻𝘁𝗲𝗿𝗰𝗲𝗽𝘁 𝗖𝗹𝗶𝗻𝗶𝗰 𝗠𝗼𝗱𝗲𝗹
with Somedeb Ball
Thursday, July 30
6 pm CET • 12 pm NY
Register now for free 👇
https://t.co/GXwp6kuYfy
@drsomedeb @Mohty_EBMT
Are we entering a therapeutic conundrum for fit patients with AML?
A thoughtful treatment algorithm which highlights the Mayo Clinic and MD Anderson approach.
@BloodCancerJnl @MayoCancerCare @UTMDAnderson @VincentRK #amlsm
https://t.co/uS33DlJc3R
In a recent interview, Yakir Moshe of @SouraskyMedCtr shared advice for community oncologists navigating the acute myeloid #leukemia treatment landscape.🩸
Watch here:
🎥 https://t.co/QNfLO4fAg8
#AMLsm #Leusm #EHA2026 @EHA_Hematology
3) Untreated #AMLsm patients were older than treated patients (81.2 vs 77.9 years). Females were more likely to be untreated than males. Patients diagnosed in 2019 or later were more likely to receive therapy, and among those, 67.3% received VEN-based therapy.
Our newest paper @YaleCancer @Yale @YaleHematology led by Dr Alain Mina where we analyzed 12,154 #AMLsm patients who were older than 75 yr in age or unfit for intensive chemotherapy to identify factors influencing the receipt of #AMLsm-directed therapy. https://t.co/4SDKsoAb4D
Retrospective study of #IC vs #HMA_Ven in #AML with chr 5/7 abnormalities
⭐️ retrospective multicenter
⭐️ unbalanced molecular distribution
⭐️ similar CR. 43% vs 52%
⭐️ similar OS age 60-75
More data to review in the paper
@Haematologica
#amlsm
https://t.co/7P1EYxA87f
Risk Prognostication After Hypomethylating Agents + Venetoclax in AML: PRISM Risk Model [Jul 2, 2026] @CLachowiez @LeukDocJZ et al. @JCO_ASCO
https://t.co/ZRKsoIoXo9 #AMLsm #leusm
https://t.co/18KYGKuYJV
@sanamloghavi thread: https://t.co/vZzJ6DMlaB
![mtmdphd's tweet photo. Risk Prognostication After Hypomethylating Agents + Venetoclax in AML: PRISM Risk Model [Jul 2, 2026] @CLachowiez @LeukDocJZ et al. @JCO_ASCO
https://t.co/ZRKsoIoXo9 #AMLsm #leusm
https://t.co/18KYGKuYJV
@sanamloghavi thread: https://t.co/vZzJ6DMlaB https://t.co/L2w9rwxXsD](https://pbs.twimg.com/media/HMu5499WAAApKng.jpg)
![mtmdphd's tweet photo. Risk Prognostication After Hypomethylating Agents + Venetoclax in AML: PRISM Risk Model [Jul 2, 2026] @CLachowiez @LeukDocJZ et al. @JCO_ASCO
https://t.co/ZRKsoIoXo9 #AMLsm #leusm
https://t.co/18KYGKuYJV
@sanamloghavi thread: https://t.co/vZzJ6DMlaB https://t.co/L2w9rwxXsD](https://pbs.twimg.com/media/HMu5uvBX0AASF9P.jpg)
![mtmdphd's tweet photo. Risk Prognostication After Hypomethylating Agents + Venetoclax in AML: PRISM Risk Model [Jul 2, 2026] @CLachowiez @LeukDocJZ et al. @JCO_ASCO
https://t.co/ZRKsoIoXo9 #AMLsm #leusm
https://t.co/18KYGKuYJV
@sanamloghavi thread: https://t.co/vZzJ6DMlaB https://t.co/L2w9rwxXsD](https://pbs.twimg.com/media/HMu5lIsW8AAGzKG.jpg)
The PRISM AML risk model for HMA+VEN is now out in @JCO_ASCO Congratulations to @CLachowiez & all investigators on this huge accomplishment addressing a much needed clinical gap.
We think it’s the Rolls-Royce Phantom of risk models!!!
Bonus: IT HAS A CALCULATOR
Try it out …. you will love it.
https://t.co/yiQkkQEZDZ
https://t.co/jqXTZ9SZ1R
🎙️ In our latest podcast, Dr Eytan Stein discusses what the future might hold for the evolution of FLT3 inhibitors in the treatment of AML.
Listen here: https://t.co/3ycGG6KIYh
#AMLsm #leusm #MedEd @Doctor_E_Stein
Intended for healthcare professionals. This educational resource is independently supported by Daiichi Sankyo. All content is developed by SES in collaboration with an expert steering committee. Funders are allowed no influence.
Last Seen Hashtags on Sotwe
monkeyapp
Seen from Indonesia
musclehunk
Seen from Brazil
momsonn
Seen from Canada
teen
Seen from Switzerland
omegle() or #monkeyappwinsfull() or #thundr() or #monkeyapp()+filter:videos
Seen from Algeria
GayDaddy
Seen from Mexico
sobrinho
Seen from Brazil
tgirl bbc
Seen from Belgium
ブラウザゲーム
Seen from Colombia
OMEGLE
Seen from United States
Most Popular Users
Elon Musk 
@elonmusk
241.3M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
113M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.1M followers
Rihanna
@rihanna
98.3M followers
NASA
@nasa
92.3M followers
Justin Bieber
@justinbieber
91.5M followers
KATY PERRY
@katyperry
89.1M followers
Taylor Swift
@taylorswift13
83M followers
Lady Gaga
@ladygaga
74.5M followers
Virat Kohli
@imvkohli
72.1M followers
Kim Kardashian
@kimkardashian
70.5M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
65M followers
Bill Gates
@billgates
64.7M followers
The Ellen Show
@theellenshow
62.4M followers
Selena Gomez
@selenagomez
62.2M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers